Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ advanced HER2+ BC based on results from the primary analysis, which the Company used to submit an NDA to the ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

The legislation will make it easier for hospitals to make improvements and harder for UMMC to open facilities outside of ...

Officials at ARM, ASGCT, and ISCT convened a small group of scientists, policy experts, religious leaders and patient ...

By Chioma Obinna Africa’s healthcare landscape is undergoing a rapid transformation, fueled by digital technologies that are ...

Press ReleaseCROSSJECT reports financial results for 2024Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing ...

Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.

Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Here are five ways community colleges have transformed because of the new funding formula: During the COVID-19 pandemic, young Texans cut community college out of their plans. One in ten students in ...

Bluesky was opening up to the public and was known as one of the many X competitors that emerged after Elon Musk acquired the ...